Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
T.MAN Pharmaceutical PCLBKK:TMAN -0.88%21 ROE % is 21.09% as of Mar. 2026, which is 31% below its 10-year median of 30.53. GuruFocus rates BKK:TMAN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 938 Drug Manufacturers companies, T.MAN Pharmaceutical PCL ranks better than 91.79% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, T.MAN Pharmaceutical PCL's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
T.MAN Pharmaceutical PCL ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, T.MAN Pharmaceutical PCL's ROE % distribution charts can be found below:
* The bar in red indicates where T.MAN Pharmaceutical PCL's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
T.MAN Pharmaceutical PCL (BKK:TMAN) has a ROE % of 21.09% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on T.MAN Pharmaceutical PCL and its competitors. This is 31% below median its historical median of 30.53. Over the past decade, T.MAN Pharmaceutical PCL's ROE % has ranged from 25.55 to 45.36. According to the industry distribution chart, T.MAN Pharmaceutical PCL ranks #77 out of 938 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is T.MAN Pharmaceutical PCL's ROE % too high?
T.MAN Pharmaceutical PCL's current ROE % of 21.09% is 31% below median its 10-year median of 30.53. Over the past 10 years, this metric has ranged from a low of 25.55 to a high of 45.36. The Drug Manufacturers industry median ROE % is 6.02. T.MAN Pharmaceutical PCL's value of 21.09% is 250.3% above this industry median. Based on the distribution chart, T.MAN Pharmaceutical PCL ranks #77 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, T.MAN Pharmaceutical PCL has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does T.MAN Pharmaceutical PCL's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, T.MAN Pharmaceutical PCL ranks #77 out of 938 companies for ROE %. This places T.MAN Pharmaceutical PCL in the top 8% of its industry — outperforming the majority of peers. The industry median ROE % is 6.02. T.MAN Pharmaceutical PCL's value of 21.09% is 250.3% above this benchmark. Historically, T.MAN Pharmaceutical PCL's own ROE % has ranged from 25.55 to 45.36 over the past decade. While the company's 10-year median is 30.53 vs. the industry median of 6.02, T.MAN Pharmaceutical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.02, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. T.MAN Pharmaceutical PCL's current ROE % of 21.09% is 250.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on T.MAN Pharmaceutical PCL and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T.MAN Pharmaceutical PCL's current ROE % is 21.09%, which is 31% below median its own 10-year median of 30.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T.MAN Pharmaceutical PCL stock overvalued right now?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a current ROE % of 21.09%. The current ROE % is 21.09%, which is 31% below median its 10-year median of 30.53 and 250.3% above the Drug Manufacturers industry median of 6.02. T.MAN Pharmaceutical PCL's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For T.MAN Pharmaceutical PCL (BKK:TMAN), the current ROE % is 21.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
21GF Score
Get the complete analysis for BKK:TMAN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TMAN has been successfully added to your 
